• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Does Extended-Release Naltrexone Worsen Psychiatric Symptoms?

Does Extended-Release Naltrexone Worsen Psychiatric Symptoms?

May 21, 2019
Brian Frankel, MD.
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Brian Frankel, MD. Dr. Frankel has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Latif Z et al, JAMA Psychiatry 2019;76(2):127–134

Extended-release (XR) naltrexone (Vivitrol) is an injectable version of naltrexone that lasts for 4 weeks and is FDA approved for opioid use disorder (OUD). Although effective, there is some concern that XR naltrexone may cause or worsen psychiatric symptoms because of its opioid blockade. Prior research has been mixed on this issue, and studies have been limited by not comparing XR naltrexone with an active control medication. This new study is the first to directly compare XR naltrexone with buprenorphine in terms of their effects on anxiety, depression, and insomnia.

The outpatient Norwegian study contained two components: a 12-week randomized controlled trial (RCT) and a 36-week follow-up study. In the RCT, 159 participants diagnosed with OUD were randomly assigned, but not blinded, to treatment with flexibly dosed daily buprenorphine/naloxone or monthly injections of XR naltrexone. At the end of 12 weeks, participants could choose treatment with buprenorphine/naloxone or XR naltrexone, and they were then followed for an additional 36 weeks.

Outcome measures included symptoms of anxiety, depression, and insomnia, as assessed by the Hopkins Symptom Checklist and the Insomnia Severity Index. These scales measure symptoms, but they are not diagnostic, and there was no mention of the prevalence and distribution of mood, anxiety, and sleep disorders between the groups.

The results showed that the two treatments were comparable. During the RCT component of this study, XR naltrexone was not significantly different than buprenorphine in terms of anxiety and depression symptoms, and it was slightly better than buprenorphine regarding ­insomnia symptoms (effect size -0.32; p = 0.008). There were no significant differences between groups in the ­follow-up component. Encouragingly, throughout all components of the study, anxiety, depression, and insomnia symptoms improved over time.

CATR’s Take
It appears that XR naltrexone does not worsen symptoms of anxiety, depression, or insomnia in people with OUD. When we are deciding between XR naltrexone and buprenorphine for OUD, the primary factors should be efficacy and patient access and preference.
Addiction Treatment
KEYWORDS naltrexone opioids research-update
Brian Frankel, MD.

More from this author
www.thecarlatreport.com
Issue Date: May 21, 2019
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Dual Diagnosis in Addiction Medicine, CATR, May/June 2019
Managing Substance-Related Agitation
Treating Co-Occurring Psychiatric Disorders
Cognitive Behavioral Therapy for Substance Use Disorders
Co-Occurring Addiction and PTSD
Oral vs Extended-Release Naltrexone for Opioid Use Disorder
Does Extended-Release Naltrexone Worsen Psychiatric Symptoms?
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    Treating Alcohol Use Disorder: A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • Substance_Use_Sites.jpeg
    Addiction Treatment

    Supervised Drug Consumption Sites

    Once controversial, research clearly shows the benefit of these sites, and they have started opening in the United States.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.